ACTR-32. NRG ONCOLOGY RTOG 1205: RANDOMIZED PHASE II TRIAL OF CONCURRENT BEVACIZUMAB AND RE-IRRADIATION VS. BEVACIZUMAB ALONE AS TREATMENT FOR RECURRENT GLIOBLASTOMA

This study sought to determine whether re-irradiation (ReRT) and concurrent bevacizumab (BEV) improves overall survival (OS) compared to BEV alone in recurrent glioblastoma (GBM). Patients (pts) were randomized 1:1 to ReRT (35 Gy/10 fractions) plus BEV (IV 10 mg/kg q2 wks) vs. BEV alone. With 160 pt...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Tsien, Christina, Pugh, Stephanie, Dicker, adam, Raizer, Jeffrey, Matuszak, Martha, Lallana, Enrico, Huang, Jiayi, algan, ozer, Taylor, Nicholas, Portelance, Lorraine, Villano, John, T Hamm, John, S Oh, Kevin, N Ali, Arif, Kim, Michelle, Lindhorst, Scott, Mehta, Minesh
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Adult Clinical Trials - Non-Immunologic
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847814/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.075
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados